The new generation of HCV drugs is undoubtedly effective, but expensive. The three medical societies plan to update their treatment guidelines by adding a section on cost-effective treatment.
The updated guideline, still in draft form, is being designed to inform physicians of the economics of HCV treatment, rather than dictate how treatment decisions should be made, according to the report.
More articles on gastroenterology:
5 GI physicians in the news – Aug. 7, 2015
FDA approves OBERA balloon for obesity treatment
What do gastroenterologists do to relax?
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
